Revised biocompatibility guidance to be completed by late summer, FDAers estimate.
This article was originally published in The Gray Sheet
Executive Summary
REVISED FDA BIOCOMPATIBILITY GUIDANCE TO BE COMPLETED BY LATE SUMMER, agency staffers predict. The guidance, which is expected to reduce device laboratory testing requirements, "should be off the press shortly," Mel Stratmeyer, Director of the Health Sciences Branch in the FDA device center's Office of Science and Technology, said June 2 at the Medical Design and Manufacturing East conference in New York City.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.